JPM Week 2024: Addressing the Latest Market Drivers and Trends for Biologics and Sterile Injectables
Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables. He shares his optimism about recent growth and progress in the Biologics and Sterile Injectables space, noting increased success in late-stage trials and expansion into larger indications. McErlane considers the various opportunities in Protein, CGT and Sterile injectables pipelines, as well as investment upticks, increases in approvals, and the need for unique manufacturing expertise in complex biologic modality value chains – specifically how Catalent’s OneBio™ offering integrates services across modalities to simply and accelerate biologics.